Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518301-18-00

Acronym

IHT-001

Enrollment

Registered

2024-12-16

Start date

2022-01-28

Completion date

Unknown

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and/or refractory acute lymphoblastic (ALL) or myeloid (AML) leukemia in patients who are not eligible for curative therapies and lack other available therapeutic options

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Poland

Outcome results